Recursion Pharmaceuticals amended a previous filing to include pro forma financial information related to its acquisition of Exscientia, which became a wholly owned subsidiary as of November 2024.
AI Assistant
RECURSION PHARMACEUTICALS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.